In vivo regulation of the Alzheimers disease beta-secretase, BACE1

阿尔茨海默病 β-分泌酶 BACE1 的体内调节

• 批准号: nhmrc : 570982
• 负责人: Dr R. M. Damian Holsinger
• 金额: $ 19.18万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/vivo-regulation-alzheimers-secretase-bace1/77364
• 关键词: vivo; regulation; Alzheimers; disease; beta

Dementia claims 1000 Australians weekly. Alzheimer's disease (AD) is the leading cause of dementia. A hallmark of AD is the presence of beta-amyloid (Ab) plaques in brain. Accumulation of Ab leads to toxicity and cell death. We will use cutting-edge technologies to reduce the level of an enzyme (BACE1) that generates Ab. This study will provide seminal information relating to in vivo regulation of Ab and establish a foundation for our ultimate goal of decreasing BACE1 and Ab in human brain.

每周有1000名澳大利亚人死于痴呆症。阿尔茨海默病（AD）是痴呆症的主要原因。阿尔茨海默病的一个标志是大脑中存在β -淀粉样蛋白（Ab）斑块。Ab的积累导致毒性和细胞死亡。我们将利用尖端技术降低一种产生Ab的酶（BACE1）的水平。这项研究将提供与Ab的体内调节有关的开创性信息，并为我们减少人脑中BACE1和Ab的最终目标奠定基础。